Epigenetic Inheritance of Disease Raises Concerns About Chemicals

Epigenetic Inheritance of Disease Raises Concerns About Chemicals

Newsletter · March 2026
Patient Education Series

Environmental Health & Cancer Risk

Toxic Inheritance: How a Single Chemical Exposure Can Shape Health Across 20 Generations

Groundbreaking new research shows that pesticides and endocrine-disrupting chemicals can reprogram reproductive cells in ways that drive disease — including prostate disease — in descendants who were never directly exposed. The implications for understanding prostate cancer risk may be profound.

|  March 2026  |  Based on peer-reviewed research and recent scientific releases

Bottom Line Up Front (BLUF)

• A landmark study published in February 2026 in the Proceedings of the National Academy of Sciences found that a single prenatal exposure to the fungicide vinclozolin caused measurable disease — including prostate and kidney disease — across 20 subsequent generations of rats, with effects worsening in later generations.
• The mechanism is epigenetic inheritance: toxic chemicals can alter the chemical "on/off switches" that control how genes are expressed, and those alterations can be stably passed down through sperm and egg cells without changing the underlying DNA sequence.
• Vinclozolin is an anti-androgenic endocrine disruptor — it blocks the testosterone receptor — making its link to male reproductive and prostate disease particularly relevant to the prostate cancer community.
• Dozens of other chemicals, including pesticides, plastics compounds (BPA, phthalates), herbicides (glyphosate, atrazine), and dioxins, have been shown to produce similar transgenerational effects in animal studies.
• Current EPA regulations do not require transgenerational testing — meaning chemicals are approved without knowing whether they reprogram reproductive cells in ways that harm future generations.
• Prostate cancer is one of the most heritable common cancers — yet known DNA mutations and common genetic variants explain only about one-third of that familial risk. This well-documented "missing heritability" gap is a prime scientific candidate for epigenetic transgenerational inheritance, which current clinical genetic testing cannot detect.
• Emerging epigenetic biomarkers may eventually allow clinicians to predict, and potentially intercept, disease susceptibility inherited from ancestral chemical exposures — a promising tool for preventive medicine.

The Landmark Study: Twenty Generations of Consequence

In February 2026, Washington State University biologist Michael K. Skinner and colleagues published a study that stopped many scientists in their tracks. Published in the Proceedings of the National Academy of Sciences, the paper followed the descendants of rats whose great-great-grandmothers had been exposed, just once, to a common fungicide called vinclozolin — for only a few days during a critical window of fetal development. The research team tracked twenty subsequent generations.

The findings were sobering. Disease did not fade with each passing generation the way most people might expect. Instead, kidney disease, prostate abnormalities, ovarian disease, and testicular disease persisted through all twenty generations studied. More troubling still: the disease got worse over time.

"The presence of disease was pretty much staying the same, but around the 15th generation, what we started to see was an increased disease situation. By the 16th, 17th, 18th generations, disease became very prominent and we started to see abnormalities during the birth process."

— Michael K. Skinner, Ph.D., Founding Director, Center for Reproductive Biology, Washington State University (WSU Insider, February 2026)

By the 22nd and 23rd generations, mothers and entire litters were dying during childbirth — a catastrophic reproductive failure in animals that had never been exposed to anything themselves. In humans, twenty generations would span roughly 500 years. A chemical exposure today could, in theory, continue to reverberate biologically well into the 26th century.

What Is Epigenetic Inheritance? A Plain-Language Explanation

Our DNA is like a master instruction book. Epigenetics refers to the system of chemical tags and structural modifications that tell the cell which pages of the book to read — and which to ignore. The most well-studied of these tags is DNA methylation: the addition of a small chemical group (a methyl group) to specific spots on the DNA strand, which typically silences genes in those regions.

In normal development, the embryo undergoes a sweeping "reset" of most epigenetic marks — a kind of molecular house-cleaning between generations. Scientists long assumed this erasure was complete. What Skinner's two decades of research have demonstrated is that some of these marks escape the reset and are stably transmitted to offspring through sperm and egg cells (the "germline"). These heritable epigenetic changes are called epimutations.

Once an epimutation is programmed into the germline, Skinner explains, it behaves much like a conventional genetic mutation — copying itself faithfully into every subsequent generation, and influencing the expression of genes in every cell type throughout the body. The critical difference from a DNA mutation is that the underlying DNA sequence is unchanged. Standard genetic tests will not detect these changes.

How Transgenerational Inheritance Works (Gestating Female Exposure)

F0

Great-grandmother (directly exposed): Pregnant female exposed to toxicant. Her own cells AND the developing fetus AND the fetal germline (future eggs/sperm) are all directly affected.

F1

Grandmother (directly exposed in womb): Fetus was present during exposure. Her developing germline was also directly exposed.

F2

Mother (directly exposed via grandmother's germline): Still considered a direct exposure generation. Epigenetic changes are being carried forward.

F3+

You and beyond (transgenerational generations): Never directly exposed. Yet epimutations programmed into the germline continue to be faithfully transmitted and can drive disease susceptibility — potentially worsening over subsequent generations.

Why This Matters Specifically for Prostate Disease

Vinclozolin is an anti-androgenic endocrine disruptor — it works by blocking androgen receptors, the molecular switches that respond to testosterone and other male hormones. This is the same receptor system that prostate cancer cells often hijack to fuel their growth, and the same system targeted by androgen deprivation therapy (ADT) and drugs like enzalutamide (Xtandi) and abiraterone (Zytiga).

Separate research by Skinner's lab has documented that ancestral vinclozolin exposure causes specific transgenerational changes in both the prostate epithelial and stromal cells of F3-generation (great-grandoffspring) male rats — including altered DNA methylation patterns, changes in gene expression, and histologically confirmed prostate disease. The authors of that study noted that these inherited molecular changes "may serve as a source of the increased incidence of prostate pathology observed in recent years."

Other industrial chemicals have been implicated as well. Research published in a major environmental toxicology review found that dioxin (the toxic component of Agent Orange), when animals are exposed prenatally, leads to higher rates of prostate disease in the directly exposed F1 generation — and that elevated kidney and prostate disease then reappears in the F3 transgenerational descendants. Dioxin remains environmentally persistent; its half-life in the human body is estimated at 7 to 11 years, and millions of people worldwide were exposed through industrial accidents, contaminated food supplies, and military herbicide use in Vietnam.

Key Chemicals Linked to Transgenerational Prostate & Reproductive Disease

Vinclozolin (fungicide, once used on grapes, strawberries, turf): Prostate disease, kidney disease, testicular disease, obesity, fertility decline — all documented transgenerationally across multiple generations.

DDT (banned insecticide, still present in environment): Transgenerational obesity, ovarian disease, sperm epimutations documented through at least F3 generation. Found in human blood samples globally.

Dioxins/TCDD (industrial contaminant, Agent Orange component): Prostate disease in F1 and kidney/prostate/ovarian disease in F3 generation. Highly persistent.

BPA and phthalates (plastics): Transgenerational reproductive disease, altered puberty timing, stress-response changes. Phthalates are ubiquitous in food packaging, personal care products.

Glyphosate (Roundup) (herbicide): Demonstrated epigenetic transgenerational inheritance of kidney, prostate, and testicular disease in rat studies. The most heavily used agricultural chemical in the world.

Atrazine (herbicide): Testicular disease, mammary tumors, early puberty onset, motor hyperactivity seen in F3 generation descendants of exposed rats.

The Missing Heritability of Prostate Cancer: A Critical Clue

One question naturally arises from all of this for any prostate cancer patient with a family history of the disease: Could epigenetic inheritance explain why prostate cancer runs in my family? The science suggests it very well might — and the answer illuminates one of the most stubborn puzzles in prostate cancer research.

Prostate cancer is among the most heritable of all common cancers. Large Scandinavian twin studies involving more than 44,000 pairs estimated that approximately 42% to 58% of prostate cancer risk is attributable to inherited factors. A man whose father or brother had prostate cancer faces roughly double the population risk. That familial signal is strong, consistent, and well established across decades of epidemiological research.

Yet despite enormous investments in genetic research — including massive genome-wide association studies (GWAS) scanning hundreds of thousands of genomes — known DNA mutations and common genetic variants collectively account for only about one-third of that heritable risk. High-risk genes like BRCA2, HOXB13, ATM, and CHEK2 are meaningful when present, but they are found in fewer than 10% of prostate cancer patients. Even combining every known DNA mutation with polygenic risk scores built from hundreds of common low-risk variants, a large share of why prostate cancer clusters in families remains biologically unexplained. Scientists call this the "missing heritability" problem.

"Rare or less-common pathogenic germline variants in cancer predisposition genes play an important role in prostate cancer, but these variants are present in fewer than 10% of men — pointing toward a significant amount of missing heritability."

— Hematology/Oncology, May 2025 review of prostate cancer genetics

This is precisely where epigenetic transgenerational inheritance becomes a compelling scientific hypothesis. Standard germline genetic testing looks exclusively at DNA sequence — it is entirely blind to epimutations, the heritable methylation changes that Skinner's research has documented transmitting faithfully across generations. A man whose genetic panel returns negative for BRCA2, HOXB13, and all other tested variants may still carry inherited epigenetic alterations that no current clinical test can detect, alterations potentially rooted in an ancestor's chemical exposure decades or even a century ago.

The timing adds a further dimension of biological plausibility. The first truly transgenerational human generation (F3) from the broad agricultural chemical exposures that began in the 1950s — DDT, organochlorines, early herbicides — would now be in their 50s and 60s, precisely the age window when prostate cancer most commonly manifests. If epigenetic inheritance is contributing to familial prostate cancer clustering in humans, the epidemiological signal from those exposures would be becoming visible right now.

What "Missing Heritability" Means for Your Family History

If you have a strong family history of prostate cancer but genetic testing has found no known mutations, this does not mean inheritance is not at work. It may mean the inheritance mechanism is epigenetic rather than genetic — operating through heritable changes to gene regulation that standard DNA sequencing cannot see.

Family history remains one of the strongest known risk factors for prostate cancer regardless of whether its molecular basis has been identified. Men with a first-degree relative (father or brother) diagnosed with prostate cancer should discuss earlier and more frequent PSA screening with their physician. The absence of a positive germline gene test does not eliminate that elevated risk.

The Scale of the Problem: One Chemical Is Just the Beginning

The February 2026 PNAS study tracked only one chemical — vinclozolin — for only as long as a rat colony could feasibly be maintained. The real-world landscape is far more complex. According to EPA figures, more than 80,000 chemicals are currently registered for commercial use in the United States. The majority have never been tested for transgenerational epigenetic effects. Many have never been adequately tested for direct toxicity either.

In the 2026 study, when researchers examined the sperm and tissue samples from the 23rd generation of rats, they found 470 significantly altered DNA methylation regions in the maternal lineage and 64 in the paternal lineage, compared to unexposed controls. Many of the same altered regions had been present ten generations earlier — confirming these epimutations are stable and heritable, not random accumulations of noise. Changes were concentrated in regions of the genome governing metabolism, hormonal signaling, and organ function.

The researchers also detected a small number of true DNA mutations — permanent sequence changes — in later generations. This suggests that, over enough generations, epigenetic instability may eventually drive conventional genetic mutations as well, blurring the boundary between epigenetic and genetic inheritance.

"Essentially, when a gestating female is exposed, the fetus is exposed. And then the germline inside the fetus is also exposed. From that exposure, the offspring will have potential effects of the exposure, and the grand offspring, and it keeps going. Once it's programmed in the germline, it's as stable as a genetic mutation."

— Michael K. Skinner, Ph.D. (WSU Insider, February 2026)

The Chronic Disease Connection

Skinner has proposed that epigenetic transgenerational inheritance may help explain one of the most puzzling features of modern public health: the relentless rise of chronic disease that cannot be fully explained by lifestyle factors, direct chemical exposure, or conventional genetics alone. The diseases that appear transgenerationally in rat studies — prostate disease, kidney disease, obesity, reproductive failure, immune abnormalities — are precisely the diseases that have been increasing in the human population over the same decades that agricultural chemical use surged.

According to the U.S. Centers for Disease Control, more than three-quarters of Americans now live with at least one chronic disease such as heart disease, cancer, or arthritis, and more than half have two or more conditions. Prostate cancer is now the second most common male cancer globally. Autism spectrum disorder has increased from 1 in 150 American children in 2000 to 1 in 31 today. Whether epigenetic inheritance plays a role in these human trends remains under active investigation, but the trajectory of animal research continues to build a mechanistically coherent case.

A Critical Regulatory Blind Spot

Current chemical safety law in the United States — governed primarily by the Toxic Substances Control Act (TSCA) — does not require manufacturers to test new chemicals for transgenerational epigenetic effects. Standard toxicology studies focus on direct exposure effects, sometimes extending to two or three generations, but typically not to the F3 or later generations where truly transgenerational effects first appear without any direct exposure. Experts like Skinner argue that regulatory agencies will need to require multigenerational studies extending to at least the F3 generation to capture these hidden harms.

The policy landscape has been moving in a complicated direction. In September 2025, the EPA under Administrator Lee Zeldin proposed significant rollbacks to the 2024 procedural framework rule for existing chemical risk evaluations under TSCA, citing concerns about regulatory burden and economic impact. The proposal was published in the Federal Register and drew substantial public comment from health and labor groups. Meanwhile, Congressional leaders have signaled plans to reopen TSCA more broadly in 2026, when the EPA's fee authority under the law comes up for renewal, raising concerns among public health advocates that hard-won chemical protections could be weakened further.

As a 2022 review in Environmental Epigenetics noted: "Governmental policies regulating toxicant exposure should take generational effects into account. A new approach that takes into consideration generational toxicity will be needed to protect our future populations."

A Path Forward: Epigenetic Biomarkers and Preventive Medicine

The same science that reveals the problem may eventually offer tools to address it. One of the most promising frontiers in this field is the development of epigenetic biomarkers — specific patterns of DNA methylation that serve as stable biological signatures of inherited disease susceptibility, detectable years or even decades before symptoms appear.

Skinner's lab has identified exposure-specific DNA methylation patterns in rat sperm that correspond to distinct diseases — separate biomarker signatures for prostate disease, kidney disease, testicular disease, and obesity, each linked to a different ancestral chemical exposure. Crucially, these biomarkers are exposure-specific: the methylation pattern from vinclozolin ancestry looks different from the pattern left by dioxin ancestry or glyphosate ancestry, potentially making it possible to identify not just that a person carries inherited susceptibility, but what type of ancestral exposure may have triggered it.

In humans, Skinner notes, his group has already identified epigenetic biomarkers associated with approximately ten different disease susceptibilities, including pregnancy-related disorders like preeclampsia. Extension of this work to prostate and other cancers is an active area of inquiry. In the future, a simple sperm or blood epigenome analysis might flag a man's inherited vulnerability to prostate disease long before PSA levels rise — enabling earlier surveillance, lifestyle interventions, or even targeted epigenetic therapies to reverse inherited methylation marks.

What You Can Do Now

Reduce exposure where practical. Choose organic produce when feasible (especially items previously treated with vinclozolin: grapes, strawberries, raspberries, lettuce). Minimize use of plastics, especially for food storage and heating. Be aware of herbicide and pesticide exposure in residential and occupational settings.

Discuss family history broadly. Because epigenetic effects can skip generations and arrive in descendants never directly exposed, traditional family cancer histories may miss the signal. A strong family history of prostate cancer is a significant risk factor regardless of whether genetic testing finds a known mutation — the missing heritability may be epigenetic.

Ask about epigenetic testing. While clinical epigenetic biomarker panels for prostate cancer susceptibility are not yet in routine use, the science is advancing rapidly. Ask your urologist or oncologist about emerging research in this area.

Stay engaged with policy. TSCA is under review in 2026. The outcome of Congressional deliberations will determine whether future chemicals are tested for the kind of multigenerational effects documented in this research.

Conclusion: The Long Shadow of a Short Exposure

The message of the February 2026 PNAS study is at once alarming and clarifying. The rising burden of chronic disease — including prostate disease — may be partly written not in our own DNA, but in the chemically rewritten epigenomes of ancestors who lived through an era of rapid, largely unregulated chemical expansion. The fact that these effects can worsen over generations, rather than fading, means that even eliminating toxic chemical exposure today would not stop the biological consequences already set in motion from decades of past use.

What this research also makes clear, however, is that epigenetics is not destiny. Unlike permanent DNA mutations, epigenetic marks are in principle reversible — they are dynamic chemical modifications, not irreversible sequence changes. The same biology that transmits the problem carries the seeds of the solution. As Skinner told WSU Insider: "This study really does say that this is not going to go away. We need to do something about it. We can use epigenetics to move us away from reactionary medicine and toward preventative medicine."

For prostate cancer patients and their families, this emerging science is a reminder that the origins of disease are complex and multigenerational — and that understanding those origins fully may open new and powerful avenues for prevention, early detection, and ultimately, treatment.

Verified Sources & Formal Citations

1. Korolenko AA, Nilsson EE, De Santos S, Skinner MK. "Stability of epigenetic transgenerational inheritance of adult-onset disease and parturition abnormalities." Proceedings of the National Academy of Sciences. 2026;123(8):e2523071123. Published February 17, 2026. https://doi.org/10.1073/pnas.2523071123
2. Korolenko AA, Nilsson EE, Skinner MK. "Generational stability of environmentally induced epigenetic transgenerational inheritance of adult-onset disease over ten mammalian generations." Environmental Epigenetics. 2025 Dec 2;11(1):dvaf033. https://pubmed.ncbi.nlm.nih.gov/41438350/
3.   WSU Insider. "Toxic exposure creates disease risk over 20 generations." Washington State University News Release, February 20, 2026. https://news.wsu.edu/press-release/2026/02/20/toxic-exposure-creates-disease-risk-over-20-generations/
4. Nilsson EE, Ben Maamar M, Skinner MK. "Role of epigenetic transgenerational inheritance in generational toxicology." Environmental Epigenetics. 2022 Feb 16;8(1):dvac001. https://pmc.ncbi.nlm.nih.gov/articles/PMC8848501/
5. Ben Maamar M, Nilsson EE, Skinner MK. "Epigenetic transgenerational inheritance and environmental justice." Epigenetics & Chromatin. 2023;16:1–17 [Environmental justice review]. PMC Article PMC10303257. https://pmc.ncbi.nlm.nih.gov/articles/PMC10303257/
6. Nilsson E, Sadler-Riggleman I, Skinner MK. "Environmentally induced epigenetic transgenerational inheritance of disease." Environmental Epigenetics. 2018;4(2):dvy016. https://academic.oup.com/eep/article/4/2/dvy016/5055600
7. Nilsson EE, Skinner MK. "Environmentally induced epigenetic transgenerational inheritance of reproductive disease." Biology of Reproduction. 2015;93(6):145. PMC6058737. https://pmc.ncbi.nlm.nih.gov/articles/PMC6058737/
8. Nilsson E, et al. "Environmental toxicant induced epigenetic transgenerational inheritance of prostate pathology and stromal-epithelial cell epigenome and transcriptome alterations: ancestral origins of prostate disease." Scientific Reports. 2019 Feb 18. PubMed PMID 30778168. https://pubmed.ncbi.nlm.nih.gov/30778168/
9. Nilsson E, et al. "Transgenerational disease specific epigenetic sperm biomarkers after ancestral exposure to dioxin." Environmental Research. 2021 Jan;192:110395. ScienceDirect. https://www.sciencedirect.com/science/article/pii/S0013935120311762
10. Ben Maamar M, Nilsson EE, Skinner MK. "Environmental induced transgenerational inheritance impacts systems epigenetics in disease etiology." NPJ Systems Biology and Applications. 2022. PMC9018793. https://pmc.ncbi.nlm.nih.gov/articles/PMC9018793/
11. Nilsson EE, Skinner MK. "Environmentally induced epigenetic transgenerational inheritance of disease susceptibility." Translational Research. 2015 Jul;165(1):12–17. PMC4148471. https://pmc.ncbi.nlm.nih.gov/articles/PMC4148471/
12. Cortes-Gutierrez EI, et al. "Epigenetic inheritance: Intergenerational effects of pesticides and other endocrine disruptors on cancer development." International Journal of Molecular Sciences. 2022;23(9):4671. https://www.mdpi.com/1422-0067/23/9/4671
13. Reddy SR, Bangeppagari M, Lee SJ. "Immune-epigenetic effects of environmental pollutants: Mechanisms, biomarkers, and transgenerational impact." Current Issues in Molecular Biology. 2025;47(9):703. https://www.mdpi.com/1467-3045/47/9/703
14. Wang A, et al. "Adaptation and changing phenotypes through transgenerational epigenetics." Epigenetics & Chromatin. 2025. PMC12351697. https://pmc.ncbi.nlm.nih.gov/articles/PMC12351697/
15.   EurekAlert! / AAAS. "Toxic exposure creates epigenetic disease risk over 20 generations." News Release, February 2026. https://www.eurekalert.org/news-releases/1117046
16. US Right to Know / HealthWire. "One exposure. Twenty generations later, the damage is still unfolding." Investigative report, February–March 2026. https://usrtk.org/healthwire/one-exposure-twenty-generations-later-the-damage-is-unfolding/
17. U.S. Environmental Protection Agency. "Procedures for Chemical Risk Evaluation Under the Toxic Substances Control Act (TSCA) — Proposed Rule." Federal Register. September 23, 2025. Docket EPA-HQ-OPPT-2025-0260. https://www.federalregister.gov/documents/2025/09/23/2025-18431
18.   Chemical & Engineering News. "Changes are coming for the main US chemicals law." C&EN, January 2026. https://cen.acs.org/policy/chemical-regulation/epa-tsca-2026
19.   International Agency for Research on Cancer (IARC). Classification of vinclozolin as "possibly carcinogenic to humans" (Group 2B). November 2025. World Health Organization. https://www.iarc.who.int/
20.   U.S. EPA. "Vinclozolin Reregistration Eligibility Decision (RED)." EPA 738-R-00-023. October 2000. https://www3.epa.gov/pesticides/chem_search/reg_actions/reregistration/red_PC-113201_1-Oct-00.pdf
21.    Hematology/Oncology. "Genetics of Prostate Cancer." May 2025 review. Hematologyandoncology.net. https://www.hematologyandoncology.net/archives/may-2025/genetics-of-prostate-cancer/
22. McHugh J, Bancroft E, Kote-Jarai Z, Eeles R. "Prostate cancer: genetics in practice now and in the future." Hereditary Cancer in Clinical Practice. 2025 Mar 25;23:11. https://pmc.ncbi.nlm.nih.gov/articles/PMC11938723/
23.   Na R, et al. "Heritability of prostate cancer: a tale of rare variants and common single nucleotide polymorphisms." PMC4885894. https://pmc.ncbi.nlm.nih.gov/articles/PMC4885894/
24.   Bancroft EK, et al. "Hereditary predisposition to prostate cancer: from genetics to clinical implications." PMC7404100. https://pmc.ncbi.nlm.nih.gov/articles/PMC7404100/
25.   Mayo Clinic Comprehensive Cancer Center. "Prostate cancer: Family history, genetics and your risk." September 4, 2024. https://cancerblog.mayoclinic.org/2024/09/04/prostate-cancer-family-history-genetics-and-your-risk/
26. Armstrong AJ, et al. "Germline and somatic testing for homologous repair deficiency in patients with prostate cancer (part 1 of 2)." Prostate Cancer and Prostatic Diseases. 2025;28:652–661. https://www.nature.com/articles/s41391-024-00901-4
27. Saliev T, et al. "Role of ethnic and genetic factors in the development of prostate cancer (Review)." World Academy of Sciences Journal. 2025;7:13. https://www.spandidos-publications.com/10.3892/wasj.2024.301
28. Paller C. "Germline and Somatic Genetic Testing in Advanced Prostate Cancer: Practical Considerations and Challenges." Presented at ESMO Annual Meeting, Berlin, October 2025. UroToday summary. https://www.urotoday.com/conference-highlights/esmo-2025/

This article is prepared for educational purposes for members of the Informed Prostate Cancer Support Group (IPCSG). It is not intended as medical advice. Patients should discuss any concerns about environmental exposures or their potential health implications with their treating physician or oncologist. The research summarized here reflects peer-reviewed animal and human epidemiological studies; direct causal conclusions for individual human health outcomes cannot always be drawn from animal models alone.